Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data

Purpose

The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip to the hospital, and overall use of healthcare resources, such as needing to go the doctor or urgent care due to illness. Pfizer is not enrolling any participants for this study. Instead, existing data from different health data sources will be used to help answer the scientific questions Pfizer is interested in learning more about.

Conditions

  • SARS-CoV-2
  • COVID-19 Vaccines

Eligibility

Eligible Ages
All ages
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • People with at least one year of pharmacy and medical enrollment in HealthVerity prior to vaccine availability - State of California or Louisiana resident for at least one year

Exclusion Criteria

  • People currently pregnant, - Individuals with discrepancies in sex and/or year of birth between HealthVerity claims and California/Louisiana immunization registry datasets - A diagnosis of COVID-19 in any setting ≤ 90 days prior to start of study or receipt COVID-19 vaccine ≤ 90 days prior to start of study.

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Arm Groups

ArmDescriptionAssigned Intervention
Vaccinated BNT162b2 recipients
  • Biological: Vaccination
    BNT162b2 vaccination
Unvaccinated BNT162b2 eligible but did not receive

Recruiting Locations

More Details

NCT ID
NCT06199934
Status
Completed
Sponsor
Pfizer